The FDA is collaborating with OpenAI to explore AI's potential in revolutionizing the drug approval process. FDA Commissioner Marty Makary emphasized the lengthy 10-year timeline for drug market entry and showcased the first AI-assisted scientific review by the agency. Although a contract with OpenAI hasn't been finalized, discussions include a project dubbed cderGPT. The initiative aims to harness AI to speed up approvals, particularly for treatments targeting diabetes and certain cancers. This aligns with the FDA's broader technological modernization efforts.
Why does it take over 10 years for a new drug to come to market? We've just completed our first AI-assisted scientific review for a product and that's just the beginning.
A small team from OpenAI has met with the FDA and two associates of Elon Musk's so-called Department of Government Efficiency multiple times in recent weeks.
Collection
[
|
...
]